CADILAHC.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally...

Stats
Šios dienos apimtis	856 777
Vidutinė apimtis	2.11M
Rinkos kapitalizacija	0.00
EPS	INR4.77 ( 2021-12-30 )
Last Dividend	INR3.50 ( 2021-07-29 )
Next Dividend	INR0 ( N/A )
P/E	7.43
ATR14	INR0 (0.00%)

Zydus Lifesciences Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BCG.NS	0.954
TIDEWATER.NS	0.948
TATVA.NS	0.941
SINTEX.NS	0.933
CLNINDIA.NS	0.932
BUTTERFLY.NS	0.932
INDLMETER.NS	0.93
GILLETTE.NS	0.929
DBL.NS	0.927
AMBICAAGAR.NS	0.925

10 Labiausiai neigiamai susiję koreliacijos
MUKANDENGG.NS	-0.954
JBMA.NS	-0.945
KIRLOSIND.NS	-0.939
GFSTEELS.NS	-0.937
FINCABLES.NS	-0.92
FOCUS.NS	-0.919
KEERTI.NS	-0.917
STAMPEDE.NS	-0.914
JSLHISAR.NS	-0.914
LINDEINDIA.NS	-0.913

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Zydus Lifesciences Finansinės ataskaitos

Annual	2022
Pajamos:	INR170.51B
Bruto pelnas:	INR68.01B (39.89 %)
EPS:	INR19.30

FY	2022
Pajamos:	INR170.51B
Bruto pelnas:	INR68.01B (39.89 %)
EPS:	INR19.30

FY	2021
Pajamos:	INR148.22B
Bruto pelnas:	INR93.42B (63.03 %)
EPS:	INR20.84

FY	2020
Pajamos:	INR138.12B
Bruto pelnas:	INR86.63B (62.72 %)
EPS:	INR11.49

Financial Reports:

No articles found.

Zydus Lifesciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Zydus Lifesciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.12 - low (37.09%) | Divividend Growth Potential Score: 3.01 - No dividend growth expected in the near future

Information

First Dividend	INR0.200	2000-05-02
Last Dividend	INR3.50	2021-07-29
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR96.45	--
Avg. Dividend % Per Year	0.19%	--
Score	1.87	--
Div. Sustainability Score	4.12
Div.Growth Potential Score	3.01
Div. Directional Score	3.57	--

Next Divdend (Est)
(2024-07-09)

INR0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.87

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.50	0.90%
2019	INR3.50	1.00%
2020	INR3.50	1.38%
2021	INR3.50	0.73%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
UBL.NS	Dividend Junior	2023-08-03	Annually	17	0.27%
POLYCAB.NS	Dividend Knight	2023-06-21	Annually	6	0.50%
JSL.NS	Dividend Junior	2023-09-15	Sporadic	22	0.26%
DLF.NS	Dividend Junior	2023-07-28	Annually	18	0.60%
AARON.NS	Dividend Junior	2023-08-28	Sporadic	5	0.36%
SOUTHBANK.NS	Dividend Junior	2023-08-17	Sporadic	25	0.42%
MONARCH.NS	Dividend Junior	2023-09-14	Annually	3	0.20%
HERANBA.NS	Dividend Junior	2023-08-17	Annually	4	0.20%
BHEL.NS	Dividend Junior	2023-08-11	Annually	21	0.26%
RAMCOIND.NS	Dividend Junior	2023-08-02	Annually	23	0.32%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.156	1.500	6.87	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.328	1.500	7.46	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	57.27	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	14.57	2.00	5.14	10.00	[0 - 30]
freeCashFlowPerShareTTM	14.57	2.00	2.71	5.43	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.470	1.000	5.49	5.49	[0.2 - 0.8]
operatingProfitMarginTTM	0.224	1.000	7.53	7.53	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.78	1.000	8.91	0	[1 - 100]
returnOnEquityTTM	0.328	2.50	8.37	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	14.57	2.00	5.14	5.43	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	14.57	2.00	5.14	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.324	1.500	-5.49	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0775	1.000	-0.562	0	[0.1 - 0.5]
Total Score				3.01

Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.